Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT00256009
Other study ID # KF 01 279545
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received November 18, 2005
Last updated May 31, 2006
Est. completion date January 2009

Study information

Verified date November 2005
Source Rigshospitalet, Denmark
Contact Lars Alling Møller, Md phd
Phone 0045 35451338
Email Lars.Alling@rh.dk
Is FDA regulated No
Health authority Denmark: National Board of Health
Study type Interventional

Clinical Trial Summary

A randomize trial: expectation or evacuatio uteri for the treatment after late abortion


Description:

A randomize trial adressing 200 women consecutively recruited from clinical practice at Rigshospitalet.Expectation: administration of 800 microgram Cytotec half an hour after delivery. Surgery: Evacuation of the uterus


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date January 2009
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

abortion at gestational age (ultrasound) 14+0 - 20+0

Exclusion Criteria:

Allergy to cytotec

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cytotec


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Outcome

Type Measure Description Time frame Safety issue
Primary Side-effect
Primary Complication
Secondary Quality of life
See also
  Status Clinical Trial Phase
Completed NCT01541293 - Intrauterine Lidocaine for Laminaria Phase 1
Completed NCT00177333 - Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens Phase 4
Completed NCT00370487 - Comparison of the Safety of First Trimester Abortions Performed by Physicians and Non-Physicians in South Africa and Viet Nam. N/A
Completed NCT00188071 - Postoperative Pain After Medical Abortion Under Local Anesthesia : Comparison of Several Analgesic Regimen N/A
Completed NCT02277249 - Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion N/A
Completed NCT00386867 - A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP N/A
Completed NCT00677755 - Medical Abortion for Emergency Contraception Failure N/A
Completed NCT02279914 - Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial N/A
Completed NCT01615731 - Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks N/A
Completed NCT01597726 - Cervical Priming Before Dilation & Evacuation N/A
Completed NCT02318212 - Dilapan-S / Dilasoft E-Registry in Induced Abortion N/A
Terminated NCT00855842 - Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion N/A
Completed NCT00330993 - Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation Phase 2
Completed NCT00382538 - Mifepristone and Mid-Trimester Termination of Pregnancy N/A
Completed NCT03080493 - Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial Phase 4
Completed NCT02485444 - Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester Abortion Phase 4
Completed NCT00969982 - Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP)) N/A
Recruiting NCT02480543 - Different Routes of Misoprostol Prior to First Trimester Surgical Abortion Phase 4
Completed NCT00870272 - Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP) N/A
Completed NCT02048098 - Misoprostol for Second Trimester Termination of Pregnancy Phase 3